HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
France Health Approvals

France Expanded Free Access Scheme In 2022 With OTC, Herbal And Homeopathic Additions

  • Data

Executive Summary

Record of OTC drugs, traditional herbal medicines and homeopathic medicines added to France's "free access" pharmacy self-selection scheme in 2022.

You may also be interested in...



France Moving Paracetamol and NSAIDs Behind Pharmacy Counter From January

Fears over patient safety will see common OTC drugs including paracetamol moved behind the counter in France from January 2020.

People On The Move: Appointments At Orkla, PAGB, Afepadi

A round-up of the latest appointments in Europe's consumer health industry: Orkla Health names BioGaia's Ducellier as its CEO; PAGB makes changes to its board; and Afepadi names Uriach's Gispert as its president.

Germany's Dermapharm Looks To Future With Arkopharma As 2022 Sales Rise

Dermapharm has high hopes for 2023 as its acquisition of Arkopharma means the firm is now the number-one and number-three player respectively in the French and Spanish supplements markets.

Table

View full table

Topics

Tags:
France Health Approvals
Latest Headlines

Bayer Relates Feeling ‘Sexy’ To Quick Relief For Allergies In Astepro Allergy Ad Campaign

Probiotics, Synbiotics May Help With Children’s Stomach Pain But Results Are Inconclusive

L’Oreal Joins Heavyweights Tackling Sustainable Surfactants With Geno Biotech

Health And Wellness Weekly Trademarks Review: 28 March

See All
UsernamePublicRestriction

Register

RS153312

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By